59 results
6-K
BYSI
BeyondSpring Inc
18 Mar 24
Current report (foreign)
8:30am
in innovative drug research and development. Dr. Lu joined the Company in October 2021 as Senior Director of Pre-Clinical and was recently promoted
6-K
EX-99.1
BYSI
BeyondSpring Inc
26 Feb 24
Current report (foreign)
8:01am
a groundbreaking technology platform for drug discovery and developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs … clinical-stage biopharmaceutical company focused on developing innovative therapies to improve clinical outcomes for patients with high unmet medical
6-K
EX-99.1
BYSI
BeyondSpring Inc
10 Jan 24
Current report (foreign)
3:00pm
platform for drug discovery and developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs, today announced … innovative therapies to improve clinical outcomes for patients with high unmet medical needs. The Company is advancing its first-in-class lead asset
6-K
EX-99.1
BYSI
BeyondSpring Inc
18 Dec 23
BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements
4:31pm
for drug discovery and developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs, today announced … : BYSI) is a global clinical-stage biopharmaceutical company focused on developing innovative therapies to improve clinical outcomes for patients
6-K
EX-99.1
BYSI
BeyondSpring Inc
30 Oct 23
Current report (foreign)
8:05am
discovery and developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs, today announced that on October … BeyondSpring
BeyondSpring (NASDAQ: BYSI) is a global clinical-stage biopharmaceutical company focused on developing innovative therapies to improve
6-K
EX-99.1
0lrshd3pm4yyi
4 Oct 23
BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements
4:00pm
6-K
EX-99.1
z71s18jhhj3j
23 Nov 22
BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements
4:30pm
6-K
EX-99.1
hpw35s olrxc8s
11 Jan 22
BeyondSpring Announces Organizational Streamlining
4:50pm
6-K
EX-99.1
kfm c2dxzb8y
30 Dec 21
Current report (foreign)
12:30pm
6-K
EX-99.1
rrezjnkxrlc 7agrxa
1 Dec 21
Current report (foreign)
8:21am
6-K
EX-99.1
7jh 8hprrj9n1pjlq
10 Nov 21
BeyondSpring Appoints Commercial Leader Mark Santos to its Board of Directors
4:05pm
6-K
EX-99.1
virqxiou1izo 2q7a
21 Sep 21
Current report (foreign)
4:17pm
6-K
EX-99.1
x2hi y64zuw5pt1
10 Sep 21
Current report (foreign)
8:30am
6-K
EX-99.1
xn1aa1t3c4qfwx
26 Aug 21
BeyondSpring Announces Exclusive Commercialization and Co-development Agreement with Jiangsu Hengrui Pharmaceuticals for Plinabulin in Greater China
7:15am
6-K
EX-99.1
g5yxmdh8rei2rask
4 Aug 21
Current report (foreign)
7:30am
6-K
EX-99.1
zgjqh
14 Jul 21
BeyondSpring Strengthens Board with the Addition of Ex-Immunomedics and Constellation Commercial Head Brendan Delaney
7:45am
F-3
c2u3c5pl
2 Jul 21
Shelf registration (foreign)
4:06pm
6-K
EX-99.1
vdvjb214 1u8m60
16 Jun 21
BeyondSpring Announces First Quarter 2021 Financial Results and Provides a Corporate Update
8:36am